SCTX Scribe Therapeutics Inc. - Common Stock
No fundamentals data yet for this ticker.
Company insiders 8 insiders · 3 officers · 4 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Benjamin L. Oakes | President, CEO | July 23, 2026 A | — | 0 | 0 | $0 |
| David Parrot | Chief Financial Officer | July 23, 2026 A | 1,333 | 2 | 0 | $39,990 |
| Svetlana Lucas | Chief Business Officer | July 23, 2026 A | 3,000 | 1 | 0 | $45,000 |
| GORDON CARL L | Director | July 27, 2026 C | 1,348,825 | 1 | 0 | $15,000,000 |
| James Dean Watson | Director | July 23, 2026 A | — | 0 | 0 | $0 |
| Joshua Bleharski | Director | July 23, 2026 A | — | 0 | 0 | $0 |
| Jennifer A Doudna | 10% owner | July 27, 2026 C | 603,547 | 0 | 0 | $0 |
| Brett Staahl | 10% owner | July 23, 2026 A | — | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 3 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Avoro Capital Advisors LLC, Avoro Ventures LLC, Aghazadeh Behzad | July 30, 2026 | 16.37% | Initial filing | Passive investment | SEC |
| ELI LILLY & Co | July 30, 2026 | 7.30% | Initial filing | Passive investment | SEC |
| ORBIMED ADVISORS LLC, ORBIMED CAPITAL GP VIII LLC | July 29, 2026 | 7.20% | Initial filing | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.